Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.892
0.00 (0.03%)
Jan 17, 2025, 4:00 PM EST - Market closed
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $24.12M in the quarter ending September 30, 2024, a decrease of -0.08%. This brings the company's revenue in the last twelve months to $93.14M, up 5.53% year-over-year. In the year 2023, Nektar Therapeutics had annual revenue of $90.12M, down -2.10%.
Revenue (ttm)
$93.14M
Revenue Growth
+5.53%
P/S Ratio
1.92
Revenue / Employee
$679,832
Employees
137
Market Cap
164.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
Dec 31, 2019 | 114.62M | -1.08B | -90.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
NKTR News
- 11 days ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 6 weeks ago - Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting - PRNewsWire
- 2 months ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire
- 2 months ago - Multiple Catalysts Ahead For Nektar Therapeutics - Seeking Alpha
- 2 months ago - Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Nektar Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire
- 2 months ago - Nektar Therapeutics to Participate in Upcoming Investor Conferences - PRNewsWire